🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Naifa L. Busaidy

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0002-3808-6378
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 9 papers. Top paper: “Acquired Secondary RAS Mutation in BRAF V600E -Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors”.

Acquired Secondary RAS Mutation in BRAF V600E -Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors

Thyroid®(2020)10.1089/thy.2019.0514
N/A
0.688DataRank · unranked
97 citations

Ramona Dadu, Pryianka Iyer, Kacey B. Wanland, Naifa L. Busaidy, Anita Ying +5 more

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study

npj Precision Oncology(2023)10.1038/s41698-022-00341-0
N/A
0.470DataRank · unranked
22 citations

Jason Roszik, Filip Jankú, David S. Hong, Shumei Kato, Aung Naing +11 more

Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-Term Outcomes in 144 Patients Over 6 Decades

The Journal of Clinical Endocrinology & Metabolism(2024)10.1210/clinem/dgae133
N/A
0DataRank · unranked
15 citations

Mimi I. Hu, Roland L. Bassett, Anita K. Ying, Mark Zafereo, Nancy D. Perrier +5 more

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations

Scientific Reports(2022)10.1038/s41598-022-05193-z
N/A
0DataRank · unranked
9 citations

Argun Akçakanat, Scott Kopetz, Coya Tapia, Xiaofeng Zheng, Huiqin Chen +12 more

Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer

Radiotherapy and Oncology(2024)10.1016/j.radonc.2024.110602
N/A
0DataRank · unranked
0 citations

Alexander Augustyn, Abdallah Mohamed, Clifton D. Fuller, Adam S. Garden, Amy C. Moreno +17 more

Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement

The Lancet Diabetes & Endocrinology(2025)10.1016/s2213-8587(25)00064-6
N/A
0DataRank · unranked
28 citations

Laura Boucai, Naifa L. Busaidy, Cosimo Durante, James A. Fagin, Sasan Fazeli +12 more

Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cells

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.02.17.637322
N/A
0DataRank · unranked
0 citations

Rozita Bagheri‐Yarmand, Muthusamy Kunnimalaiyaan, Paola Miranda Mendez, Joseph L. Kidd, Ali Dadbin +18 more

Physical activity and dexamethasone for cancer related fatigue: A preliminary placebo controlled randomized control trial.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.12050
N/A
0DataRank · unranked
0 citations

Vicente Valero, Brandon G. Smaglo, Michael J. Overman, Arvind Dasari, Robert A. Wolff +8 more

Therapeutic Potential of Ralimetinib, a p38/MAPK14 Inhibitor, in Anaplastic Thyroid Cancer

(2022)10.52519/00062
N/A
0DataRank · unranked
0 citations

Ali Dadbin, Ying C. Henderson, Elena McBeath Fujiwara, Clifford Stephan, Roza Nurieca +8 more